logo
Diagnosing Medicaid Cuts To Hospitals In The One, Big, Beautiful Bill

Diagnosing Medicaid Cuts To Hospitals In The One, Big, Beautiful Bill

Forbes9 hours ago
WASHINGTON, DC - JULY 03: U.S. Speaker of the House Mike Johnson (R-LA) shakes hands with Rep. Jodey ... More Arrington (R-TX) alongside fellow House Republicans during an enrollment ceremony for H.R. 1, the One, Big, Beautiful Bill Act at the U.S. Capitol on July 03, 2025 in Washington, DC. The House passed the sweeping tax and spending bill after winning over fiscal hawks and moderate Republicans. The bill makes permanent President Donald Trump's 2017 tax cuts, increase spending on defense and immigration enforcement and temporarily cut taxes on tips, while at the same time cutting funding for Medicaid, food assistance for the poor, clean energy and raises the nation's debit limit by $5 trillion. (Photo by)
Since the pandemic struck the U.S., most Americans have developed a keen appreciation of their hospitals and an equal awareness of how fragile these hospital systems really are. Which is why it's critical to understand the role that Medicaid and Medicaid State-directed payments (SDPs) play in the survival of what are known as Safety Net Hospitals. And what's even more important is how the passage of the One Big, Beautiful Bill Act will now affect Medicaid and those SDPs, supporting these hospitals.
So what are Safety Net Hospitals and what do they do? As the name implies, these hospitals play a critical role in the U.S. Healthcare system, they are literally the lifeline for vulnerable populations, including those who are uninsured or have Medicaid. They serve as a 'safety net' by offering services regardless of a patient's ability to pay or their insurance status. These hospitals are often located in low-income communities and rural areas.
These hospitals also often operate on fragile margins (approximately 39% experience negative margins), and their reserve funds, an indicator of stability, are not comforting. Without adequate reserve funding, a hospital or nursing home is unable to function in the event of a downturn in reimbursements. Inadequate cash reserves, measured in the number of days the facility can continue operating with no or delayed income, portend the collapse or even closure of the operation.
What is the financial lifeblood for these hospitals are the aforementioned SDPs, this payment arrangement permit states under 42 CFR 438.6(c) to make supplemental payments to hospitals for Medicaid patients which can amount to even more than Medicare payment coverage. This funding is critical in covering hospital operations and when you consider that the days of cash on hand in 1 in 10 hospitals is less than 110 days, they are literally rated 'Vulnerable' or worse, "Highly Vulnerable."
The Rural Health Transformation Program
The Act does acknowledge the fragility of rural hospitals and has an initiative called The Rural Health Transformation Program which will appropriate $10 billion per fiscal year to Centers for Medicare & Medicaid Services (CMS) for fiscal years 2026-2030, for a total of $50 billion over five years to help them. But this deficit math simply doesn't add up and even the details of their administration are vague. Adding to the problem, the The Act makes it more difficult for states to close payment shortfalls by restricting their ability to use provider taxes to boost Medicaid payments. This further limits resources for hospitals and increases financial pressure, especially in states that have used these mechanisms to support rural and Safety Net Hospitals.
According to Becker's Hospital Review, for the first time in the last decade, the average number of days cash on hand dropped below 200 to 196.8. The upper half of U.S.-based nonprofit acute healthcare providers reported an average of 292 days, while the lower half reported an average of 128 days.
Healthcare profession teamwork and doctor service concept - International medical staff group of ... More doctors, nurses and surgeon specialist standing with stethoscopes in the hospital.
This is more than a hypothetical forecast. A recent report documents 18 hospital and emergency department closures or forced mergers so far this year. Another study found that several hospitals and health systems are reducing their workforces or jobs amid financial and operational challenges. To cite one example, Columbus (Ind.) Regional Health (CRH) notified the state that it will lay off 50 employees. The layoffs come as the health system plans to close its inpatient rehabilitation unit and the CRH Orthopedics and Sports Medicine outpatient practice, according to a news release dated June 30.
Unsurprisingly, the closures negatively affect local healthcare access with broader consequences for the community and its economy. Layoffs and closures, especially in rural or smaller communities, often result in fewer available services, longer waiting times, and, in some cases, the complete loss of essential departments, such as emergency rooms or maternity wards.
As a result of these cutbacks, medical care is compromised and everyone suffers. . With fewer staff members, remaining employees face increased workloads and higher stress, which can lead to burnout and a decline in morale. This often translates to longer wait times, rushed patient interactions, and increased risk of medical errors. Under such circumstances, healthcare workers often experience burnout, job insecurity, and increased turnover, all of which exacerbates staffing shortages and negatively impacts patient care. Many hospitals, especially those with negative. Many hospitals, especially those with already negative or low operating margins, may be forced to reduce services, lay off staff, or close altogether. This risk is especially acute for rural hospitals, which often operate on thin margins and heavy reliance on Medicaid funding.
Healthcare facility closures, especially in rural areas, have a ripple effect on the communities they once served because hospitals are often among the largest local employers. Workforce reductions decrease household incomes, reduce local consumer spending, and shrinking tax revenues, can jeopardize funding for schools and infrastructure. The multiplier effect means that each healthcare job supports additional jobs in related sectors such as food services, transportation, and construction.
Vulnerable populations are disproportionately affected by cutbacks, closures, and mergers of healthcare facilities. Cuts to administrative and support roles impact services for seniors, non-English speakers, and other vulnerable groups, reducing their ability to access care and navigate the health system.
In the long term, hospital closures and job cuts can result in a 14% reduction in healthcare-sector employment and may exacerbate ongoing economic decline; again, rural communities are disproportionately affected. These changes can make it harder to recruit healthcare professionals in the future, further eroding local healthcare infrastructure.
Why are smaller hospitals and rural hospitals already so vulnerable? The answer is multi-factorial, as they face financial challenges and layoffs due to a combination of structural, economic, and workforce-related factors. And there are no quick fixes that legislation can address.
With rural hospitals particularly vulnerable to Medicaid cuts, KFF analyses (formerly known as The Kaiser Family Foundation estimate a $50–$155 billion reduction in federal Medicaid spending for these areas over the next 10 years. KFF projects more than 1.8 million rural residents will lose Medicaid coverage. Many rural hospitals may be forced to choose between maintaining services, retaining staff, or shutting down, which would cause patients to travel long distances for care.
Smaller hospitals have significant fixed costs ('keeping the lights on') that do not scale down when they experience lower patient volume, making their cost per patient higher compared to larger hospitals. Larger hospitals benefit from economies of scale, as they spread these costs over a greater number of patients.
As noted above, rural and small hospitals typically generate less revenue and have lower occupancy rates, making them more susceptible to financial volatility and downturns. They not only lack the financial reserves but also the diverse service lines that help larger hospitals weather economic shocks.
Many small hospitals, especially in rural areas, serve a higher proportion of patients who are covered by Medicaid, Medicare, or who are uninsured. Federal payers reimburse at lower rates, often below the cost of care, resulting in chronic financial losses. Private insurers also tend to pay small hospitals less for the same services compared to larger facilities.
What compounds this even more are Medicaid cuts in the new federal budget that are expected to increase uncompensated care. The cuts are projected to increase the number of uninsured Americans by 11.8 million, ballooning uncompensated care. This will strain hospital finances, as more patients will be unable to pay for services.
Medicare cuts may be next. If the bill increases the federal deficit as projected, it could trigger approximately $500 billion in mandatory Medicare cuts, potentially resulting in a 4% reduction in payments to hospitals and other providers, unless Congress acts to prevent these cuts.
Smaller hospitals face unique workforce challenges as they struggle to attract and retain qualified healthcare professionals. Often, they rely on expensive temporary staff (locums) to fill gaps, which further increases costs. The lack of prestige, professional isolation, and fewer opportunities for advancement make recruitment and retention more difficult compared to larger, urban hospitals.
In summary, Medicaid cuts will have unintended consequences. Hospital and health system workforce reductions directly reduce healthcare access and quality for all patients, residents, destabilize local economies, and create a cycle of declining health and economic outcomes, especially in rural and underserved areas. Hospitals with high shares of Medicaid patients, particularly in rural and low-income urban areas, will be the most affected and may face existential threats due to the combined effects of coverage losses, reduced payments, and increased uncompensated care.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CELFULL Unveils Celfavor NADH Microcapsules: A Breakthrough in Stability That Reshapes the Anti-Aging Industry
CELFULL Unveils Celfavor NADH Microcapsules: A Breakthrough in Stability That Reshapes the Anti-Aging Industry

Yahoo

time44 minutes ago

  • Yahoo

CELFULL Unveils Celfavor NADH Microcapsules: A Breakthrough in Stability That Reshapes the Anti-Aging Industry

CORAL SPRINGS, FL / / July 4, 2025 / CELFULL, a biotechnology company with over 25 years of expertise in anti-aging science, has announced a major breakthrough in longevity innovation: the global launch of Celfavor® NADH Microcapsules, a patented delivery system that resolves the century-long challenge of NADH instability. Journal papers related to NADH This revolutionary technology-protected by seven international invention patents across the U.S., China, Japan, Canada, and South Korea-delivers unprecedented improvements in stability, bioavailability, and targeted delivery, marking a new era in anti-aging therapeutics known as the "Microcapsule Age." To accelerate research across the globe, CELFULL has also launched its Global Research Sharing Program, offering free access to the Celfavor® NADH raw material to scientific institutions worldwide. Celfavor®NADH The only effective NADH - Celfavor ® NADH "The discovery of the therapeutic effect of stabilized NADH is more important to humankind than the discovery of antibiotics." noted Nobel Laureate Sir John Eccles, underscoring the importance of this innovation. NADH stands for "nicotinamide adenine dinucleotide (NAD) + hydrogen (H), often dubbed the "King of Anti-Aging Molecules," plays a central role in mitochondrial energy production, antioxidant defense, and the activation of longevity proteins. However, its inherent instability-sensitive to heat, light, oxygen, and stomach acid-has severely limited its clinical applications. Conventional NADH degrades by over 70% in one month at room temperature and must be stored at -20°C, making practical use difficult. 7 patents have been certified CELFULL's research team, led by its AI-powered Multi-Target Anti-Aging Institute, spent over a decade solving this problem. The result: Celfavor® NADH Microcapsules, a proprietary technology featuring 250-350μm microcapsules that protect NADH with a multi-core soluble shell made from food-grade materials. In stability tests simulating harsh conditions (40°C / 75% RH), traditional NADH retained only 3.5% of its activity after six months. By contrast, Celfavor® NADH maintained 98.3% activity-demonstrating over 6x shelf-life extension, even without refrigeration or light shielding. The stability of Celfavor® NADH microspheres The Celfavor® NADH Microcapsule system delivers innovation across four dimensions: 1. Enhanced Stability: Microcapsules shield NADH from air, moisture, light, and stomach acid, preserving its full potency in gastrointestinal conditions for up to 4 hours. 2. Targeted Release: Using AI-optimized wall material, the system enables "zero release in the stomach and sustained release in the intestine." Simulated intestinal studies show 24-hour continuous release, extending absorption time by 5-8x. 3. Superior Bioavailability: In human trials, a daily dose of 40mg led to a 98% increase in blood NAD⁺ levels, a 3.2x improvement over regular NADH. Performance also surpassed other NAD⁺ precursors like NMN and NR. 4. Formulation Flexibility: Unlike unstable NADH, Celfavor® NADH can be safely co-formulated with vitamins, coenzymes, or peptides in single or multi-ingredient capsules. Celfavor ® NADH microsphere advanced technology surpasses others Celfavor® NADH Microcapsules have been granted seven invention patents and passed all 12 safety evaluations, including cytotoxicity and long-term toxicity tests. It is currently the only NADH raw material globally to pass full-spectrum safety certification. The only globally certified raw material for toxicology and safety experiments "We are not just creating better products-we are building a platform for the future of longevity," said Dr. Juliane Hitzel, CEO of CELFULL. "With this microcapsule technology, we're launching new delivery systems for vitamins, peptides, and more. And by sharing our raw materials with global researchers, we're fostering a collaborative ecosystem that accelerates anti-aging science." From solving the NADH stability problem to advancing intelligent delivery systems, CELFULL's innovation signals a major milestone in human longevity science. As the Celfavor® NADH Microcapsule technology rolls out globally, the anti-aging industry enters a new chapter-one defined by precision, efficiency, and collaboration. For business cooperation or research partnerships, please contact:maggie@ | Email: maggie@ SOURCE: CELFULL View the original press release on ACCESS Newswire Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Maximise Your Portfolio's Returns with These 3 US Healthcare Stocks
Maximise Your Portfolio's Returns with These 3 US Healthcare Stocks

Yahoo

timean hour ago

  • Yahoo

Maximise Your Portfolio's Returns with These 3 US Healthcare Stocks

With persistent macro uncertainty and shifting market trends, healthcare remains one of the most defensive and fundamentally sound sectors for investors. The US healthcare industry continues to deliver both stability and long-term growth potential. In the latter half of 2025, these three healthcare stocks emerge as top picks for their compelling mix of innovation and favourable industry trends. Johnson & Johnson (J&J) is a global healthcare company with its core businesses in innovative medicine and MedTech. In the first quarter of 2025 (1Q 2025), J&J reported 2.4% year-on-year (YoY) increase in revenue, bringing in US$21.9 billion. This growth can be attributed to a strong revenue growth of 4.2% YoY in innovative medicine. A key driver for the rise is the 20.4% YoY in revenue growth in the oncology segment. This increase is due to medicine such as DARZALEX and ERLEADA experiencing share gains amid market growth.J&J's MedTech division recorded a strong 4.1% YoY revenue growth. The cardiovascular segment led this jump in revenue with a 17% YoY revenue growth. This growth is due to strong global procedure volumes and successful new product launches. The firm's internal forecast for sales of its key products by 2027/2028 is also higher than current market estimates. For instance, its pipeline product, the intravesical drug releasing system, is forecasted to have three times the product sales compared to current market estimates by 2027/ presents an opportunity for investors to capitalise on the potential upside which is not yet priced into the stock. This upside will be driven by J&J's internal forecasts, which signal confidence in its operations. Thermo Fisher is a top name in biopharmaceutical research, particularly in drug discovery and 1Q 2025, Thermo Fisher reported revenue of US$10.36 billion, along with organic revenue growth of 1% YoY. The firm's net profits climbed 13.5% YoY to US$1.5 billion in 1Q 2025. This strong growth was supported by the increased operational efficiencies with the partnership with the Chan Zuckerberg Institute for Advanced Biological partnership pioneers new technologies for improved human cell visualisation, providing scientists with better data insights and accelerating research cycles. In February 2025, Thermo Fisher also announced a US$4.1 billion acquisition of Solventum's Purification & Filtration Purification & Filtration business offerings enhance Thermo Fisher's current bioproduction services. This acquisition boosts Thermo Fisher's biologics production capabilities, thereby improving productivity. This deal also opens opportunities to cross-sell filtration and purification solutions alongside existing bioprocessing offerings. These developments demonstrate an effective strategic fit and may result in service margin expansion. UnitedHealth Group runs two primary businesses – UnitedHealthcare for healthcare insurance plans and Optum for technology-based healthcare services. UnitedHealth Group reported a 9.8% YoY increase in revenue in 1Q 2025, reaching US$109.6 billion. The company's net margin also improved to 5.7% in the same quarter. The previous year's quarter saw a net loss margin of 1.4%. The better performance was attributed to a strong performance for both UnitedHealthcare and Optum. In 1Q 2025, UnitedHealthcare's revenue grew by 12.2% YoY to US$84.6 billion. This growth was driven by a rise of 700,000 in the number of self-funded commercial plans sold. Another factor was the increased participation in senior and community-based offerings with 545,000 new members. In the same period, Optum saw an increase in revenue of 4.6% YoY to US$63.9 billion. This rise is led by a growth of Optum Rx which had an increase of 13 million scripts from new clients and deepening of existing relationships compared to 2024. Optum Insight also introduced artificial intelligence claim processing tools which increase productivity by over 20%. Moving forward, Optum Health announced its continued expansion of value-based care to serve 650,000 new patients in 2025. As the healthcare landscape transforms, these three companies offer stand-out opportunities amid uncertain markets. With these companies' blend of innovation and strong fundamentals, they provide a defensive anchor along with room for growth. These three stocks are well-positioned to deliver meaningful returns. It's a good idea to consider adding this trio into your buy watchlist of growth stocks. Generative AI is reshaping the stock market, but not in the way most investors think. It's not just about which companies are using AI. It's about how they're using it to unlock new revenue, dominate their markets, and quietly reshape the business world. Our latest FREE report 'How GenAI is Reshaping the Stock Market' breaks the hype down, so you can invest with greater clarity and confidence. Click here to download your copy today. Follow us on Facebook, Instagram and Telegram for the latest investing news and analyses! Disclosure: Gabriel Lim does not own shares in any of the companies mentioned. The post Maximise Your Portfolio's Returns with These 3 US Healthcare Stocks appeared first on The Smart Investor. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store